Acute cytotoxicity and apoptotic effects after L-Pam exposure in different cocultures of the proximal and distal respiratory systemPOHL, Christine; HOFMANN, Helene; MOISCH, Michaela et al.Journal of biotechnology. 2010, Vol 148, Num 1, pp 31-37, issn 0168-1656, 7 p.Conference Paper

Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalanKÜHNE, Annett; KAISER, Rolf; BROCKMÖLLER, Jürgen et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 7, pp 505-517, issn 1744-6872, 13 p.Article

Cellular pharmacokinetics of the phenylalanine mustardsVISTICA, D. T.Pharmacology & therapeutics (Oxford). 1983, Vol 22, Num 3, pp 379-406, issn 0163-7258Article

Melphalan pharmacokinetics in children with malignant disease : influence of body weight, renal function, carboplatin therapy and total body irradiationNATH, Christa E; SHAW, Peter J; MONTGOMERY, Kay et al.British journal of clinical pharmacology. 2005, Vol 59, Num 3, pp 314-324, issn 0306-5251, 11 p.Article

Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat modelGLEHEN, O; STUART, O. A; MOHAMED, F et al.Cancer chemotherapy and pharmacology. 2004, Vol 54, Num 1, pp 79-84, issn 0344-5704, 6 p.Article

Initiates Skleromyxödem: Erfolgreiche Therapie mit Melphalan = Initial scleromyxedema. Successful treatment with melphalanSCHUBERT, K; STEIN, A; MEURER, M et al.Hautarzt. 2002, Vol 53, Num 7, pp 478-482, issn 0017-8470Article

The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2HARRISON, Luke R. E; OTTLEY, Christopher J; PEARSON, D. Graham et al.Biochemical pharmacology. 2009, Vol 77, Num 10, pp 1586-1592, issn 0006-2952, 7 p.Article

Interpreting cell cycle effects of drugs : the case of melphalanLUPI, Monica; CAPPELLA, Paolo; MATERA, Giada et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 443-457, issn 0344-5704, 15 p.Article

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivativesGULLBO, Joachim; TULLBERG, Marcus; VABENØ, Jon et al.Oncology research. 2003, Vol 14, Num 3, pp 113-132, issn 0965-0407, 20 p.Article

Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivoROTHBARTH, Joost; KOEVOETS, Cindy; TOLLENAAR, Rob A. E. M et al.Biochemical pharmacology. 2004, Vol 67, Num 9, pp 1771-1778, issn 0006-2952, 8 p.Article

Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignanciesMOUGENOT, Philippe; PINGUET, Frédéric; FABBRO, Michel et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 6, pp 503-512, issn 0344-5704, 10 p.Article

Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusionCHENG, Tsung-Yen; GRUBBS, Elizabeth; FRIEDMAN, Henry et al.The American journal of surgery. 2003, Vol 186, Num 5, pp 460-467, issn 0002-9610, 8 p.Article

Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m²)PALUMBO, A; BRINGHEN, S; MUSTO, P et al.Leukemia. 2004, Vol 18, Num 1, pp 133-138, issn 0887-6924, 6 p.Article

Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma: A reviewJABBOUR, Pascal; CHALOUHI, Nohra; TJOUMAKARIS, Stavropoula et al.Journal of neurosurgery. Pediatrics. 2012, Vol 10, Num 3, pp 175-181, issn 1933-0707, 7 p.Article

Not too little, not too much—just right! (Better ways to give high dose melphalan)SHAW, P. J; NATH, C. E; LAZARUS, H. M et al.Bone marrow transplantation (Basingstoke). 2014, Vol 49, Num 12, pp 1457-1465, issn 0268-3369, 9 p.Article

A stability-indicating method for the determination of melphalan and related impurity content by gradient HPLCBRIGHTMAN, K; FINLAY, G; JARVIS, I et al.Journal of pharmaceutical and biomedical analysis. 1999, Vol 20, Num 3, pp 439-447, issn 0731-7085Article

Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosisCESARO, Simone; GAZZOLA, Maria Vittoria; MESSINA, Chiara et al.American journal of hematology. 2003, Vol 72, Num 2, pp 143-146, issn 0361-8609, 4 p.Article

Reticulate scleroderma after isolated limb perfusion with melphalanLANDAU, M; BRENNER, S; GAT, A et al.Journal of the American Academy of Dermatology. 1998, Vol 39, Num 6, pp 1011-1012, issn 0190-9622Article

Combination of the new minor groove alkylator tallimustine and melphalanTAGLIABUE, G; FILIPPINI, C; UBEZIO, P et al.European journal of cancer (1990). 1997, Vol 33, Num 2, pp 284-287, issn 0959-8049Article

Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors: Clinical articlePETERSON, Eric C; MOHAMED SAMY ELHAMMADY; QUINTERO-WOLFE, Stacey et al.Journal of neurosurgery. 2011, Vol 114, Num 6, pp 1603-1608, issn 0022-3085, 6 p.Article

Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipientsNATH, Christa E; SHAW, Peter J; MONTGOMERY, Kay et al.British journal of clinical pharmacology. 2007, Vol 64, Num 2, pp 151-164, issn 0306-5251, 14 p.Article

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complexGOMEZ-BOUGIE, Patricia; OLIVER, Lisa; LE GOUILL, Steven et al.Oncogene (Basingstoke). 2005, Vol 24, Num 54, pp 8076-8079, issn 0950-9232, 4 p.Article

Factors influencing the chemosensitization of melphalan by misonidazoleRANDHAWA, V. S; STEWART, F. A; DENEKAMP, J et al.British journal of cancer. 1985, Vol 51, Num 2, pp 219-228, issn 0007-0920Article

Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasmaSPARIDANS, Rolf W; MARTENS, Irene; VALKENBURG-VAN IERSEL, Liselot B. J et al.Journal of chromatography. B. 2011, Vol 879, Num 21, pp 1851-1856, issn 1570-0232, 6 p.Article

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1GULLBO, Joachim; WICKSTRÖM, Malin; TULLBERG, Marcus et al.Journal of drug targeting. 2003, Vol 11, Num 6, pp 355-363, issn 1061-186X, 9 p.Article